Stampidine is a possible next-generation Pre-exposure prophylaxis (PrEP) candidate to prevent the sexual transmission of HIV-1. The compound exhibited remarkable subnanomolar to low nanomolar in vitro antiretroviral potency against genotypically and phenotypically nucleoside reverse transcriptase inhibitor (NRTI)-resistant primary clinical HIV isolates, non-nucleoside RT-resistant HIV-1 isolates and did not cause any maternal toxicity, developmental toxicity or teratogenicity in rabbits treated at 10 - 40 mg/kg/day dose levels References: Uckun FM, Cahn P, Qazi S, D'Cruz O. Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS. Expert Opin Investig Drugs. 2012 Apr;21(4):489-500. doi: 10.1517/13543784.2012.664635. Epub 2012 Feb 24. Review. PubMed PMID: 22360744.

纯度：≥98%

CAS：217178-62-6